Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01448174
Recruitment Status : Completed
First Posted : October 7, 2011
Last Update Posted : October 7, 2014
Information provided by (Responsible Party):
Alicja E. Grzegorzewska, Poznan University of Medical Sciences

Brief Summary:

Hyperlipidemia and atherosclerosis lead to cardiovascular diseases and are an indirect cause of increased death rate in the general population. This association is still more evident in specific subpopulations, like patients with advanced chronic kidney disease (CKD), especially hemodialysis (HD) patients, due to a higher prevalence of lipid disturbances and atherosclerosis compared to the general population. Cardiovascular events in CKD patients are frequently associated with traditional risk factors, including diabetes, male sex, hypertension, dyslipidemia and advanced age. However, these factors failed to fully account for the increased risk of cardiovascular events in CKD. The efforts are made to identify new risk factors that contribute to the development of atherosclerosis and participate in causes of cardiovascular death. In 2003, there were identified peptides designated salusin-alpha and salusin-beta. Development of atherosclerosis may be suppressed by salusin-alpha. Salusin-alpha may have a lipid lowering effect, similar to that of statins.

The purpose of this study is to investigate whether 1) salusin-alpha is associated with lipid metabolism of HD patients (without or with metabolic syndrome or type 2 diabetes mellitus), similarly or not like in healthy or obese subjects; 2) treatment with atorvastatin and its effects are associated with changes in plasma salusin-alpha concentration, if so - whether it is dependent on the direct influence of atorvastatin on salusin-alpha or associated with a decrease in serum lipid level; 3) salusin-alpha may predict mortality in HD patients.

Condition or disease Intervention/treatment Phase
Renal Failure Chronic Requiring Hemodialysis Metabolic Syndrome Diabetes Mellitus Type 2 Hyperlipidemia Drug: Atorvastatin Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 310 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Basic Science
Official Title: Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Study Start Date : October 2011
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Arm Intervention/treatment
Active Comparator: atorvastatin

The prospective, randomized, double-blind, placebo-controlled study:

  • will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)
  • 130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.

Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).

The prospective, observational study:

- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia

Drug: Atorvastatin

Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:

  • atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or
  • placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks.
Other Name: ATC: C 10 AA 05

No Intervention: Lifestyle counseling

Protocol of the prospective study in obese persons:

  • after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity
  • follow-up for 30 weeks (measurement of body weight every week).
No Intervention: The controls (healthy volunteers)

Primary Outcome Measures :
  1. normalization of serum LDL cholesterol [ Time Frame: 30 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

For HD patients:

  • HD vintage at least 3 months
  • signed consent for participation in the study

For obese persons:

  • BMI > 30 kg/m2
  • eGFR > 60 ml/min/1.73 m2 BSA
  • interest in weight loss according to weight loss diet protocol (WLDP)
  • signed consent for participation in the study

For controls (healthy volunteers):

  • declared health, comfort
  • no substantial changes in the medical interview and physical examination
  • no medication
  • signed consent for participation in the study

Exclusion Criteria:

For HD patients:

  • active thyroid gland disease and/or thyreotropic medication
  • treatment with corticosteroids, immunosuppressants or hormones
  • treatment with statins or fibrates in 6 weeks before the study commencement
  • diagnosis of genetic lipid abnormalities
  • neoplastic disease
  • acute coronary syndrome and/or cerebral stroke in 6 months before the study commencement
  • surgery in 3 months before the study commencement
  • plasma activities of ALT and/or AST exceeding 3 times the upper laboratory normal limit
  • non compensated diabetes mellitus

For obese persons:

  • a known history of moderate or severe cardiovascular disease, stroke or transient ischemic attack
  • uncontrolled hypertension
  • severe dyslipidemia (triglycerides > 500 mg/dl, total cholesterol > 350 mg/dl) or taking lipid-lowering agents at the recruitment or 6 weeks before
  • serious chronic disease requiring active treatment (example with glucocorticoids, antineoplastic agents, psychoactive agents, bronchodilators on a regular basis, insulin or oral hypoglycemic drugs)
  • women of child-bearing potential using an effective form of hormonal birth control, pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01448174

BBraun Avitum Dialysis Center
Nowy Tomyśl, Wielkopolska, Poland, 64-300
Sponsors and Collaborators
Poznan University of Medical Sciences
Study Chair: Alicja E. Grzegorzewska, MD, PhD Chair and Department of Nephrology, Transplantology and Internal Diseases
Principal Investigator: Leszek Niepolski, MD, PhD BBraun Avitum Dialysis Center

Responsible Party: Alicja E. Grzegorzewska, Full Professor, Poznan University of Medical Sciences Identifier: NCT01448174     History of Changes
Other Study ID Numbers: ALGN-001
First Posted: October 7, 2011    Key Record Dates
Last Update Posted: October 7, 2014
Last Verified: October 2014

Keywords provided by Alicja E. Grzegorzewska, Poznan University of Medical Sciences:

Additional relevant MeSH terms:
Diabetes Mellitus
Metabolic Syndrome X
Renal Insufficiency
Diabetes Mellitus, Type 2
Kidney Failure, Chronic
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Resistance
Kidney Diseases
Urologic Diseases
Lipid Metabolism Disorders
Renal Insufficiency, Chronic
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors